Cargando…

Successful Improvement of Metabolic Disorders, Including Osteopenia, by a Dopamine Agonist in a Male Patient with Macro-Prolactinoma

Patient: Male, 43 Final Diagnosis: Prolactinoma Symptoms: — Medication: — Clinical Procedure: Treatments by a dopamine agonist Specialty: Endocrinology and Metabolic OBJECTIVE: Unknown ethiology BACKGROUND: Bone metabolic disorders in patients with prolactinoma have not been fully characterized. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takeno, Ayumu, Yamamoto, Masahiro, Okazaki, Kyoko, Yamaguchi, Toru, Toshitsugu, Sugimoto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792224/ https://www.ncbi.nlm.nih.gov/pubmed/26971354 http://dx.doi.org/10.12659/AJCR.894712

Ejemplares similares

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
por: Liu, Xiaoshuang, et al.
Publicado: (2019)

Experience with Dopamine Agonists in the Treatment of Prolactinomas
por: Barabash, Nadiya Ye., et al.
Publicado: (2022)

Predictors of dopamine agonist resistance in prolactinoma patients
por: Vermeulen, Elle, et al.
Publicado: (2020)

Administration of anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody for the treatment of osteoporosis was associated with amelioration of hepatitis in a female patient with growth hormone deficiency: a case report
por: Takeno, Ayumu, et al.
Publicado: (2016)

Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?
por: De Sousa, Sunita M C
Publicado: (2022)

Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists
por: Babey, Muriel, et al.
Publicado: (2010)

Dopamine agonist resistant prolactinomas: any alternative medical treatment?
por: Souteiro, P., et al.
Publicado: (2019)

Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists
por: Tang, Hao, et al.
Publicado: (2021)

Long-term Outcome of Microscopic Transsphenoidal Surgery for Prolactinomas as an Alternative to Dopamine Agonists
por: Park, Kawngwoo, et al.
Publicado: (2021)

PMON169 D2R Expression in Dopamine-Agonist Resistant Prolactinomas
por: Levine, Alice, et al.
Publicado: (2022)

Effect of Tamoxifen on the Management of Dopamine Agonist-Resistant Prolactinomas: A Systematic Review
por: Bazuhair, Tuqa, et al.
Publicado: (2023)

Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas
por: Gao, Hua, et al.
Publicado: (2015)

Prolactinomas Resistant to Treatment With Dopamine Agonists: Long-Term Follow-Up of Six Cases
por: Gonzaga, Maria de Fátima de Magalhães, et al.
Publicado: (2018)

SUN-448 Giant Prolactinomas: A Follow-Up of 25 Years with Dopamine Agonists
por: Mallea Gil, Susana, et al.
Publicado: (2019)

Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis
por: Byberg, Sarah, et al.
Publicado: (2019)

The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis
por: Zou, Yunzhi, et al.
Publicado: (2021)

Change in Insulin Sensitivity and Lipid Profile After Dopamine Agonist Therapy in Patients With Prolactinoma
por: Khalil, Ghayyur, et al.
Publicado: (2021)

Morbid Obesity Due to Prolactinoma and Significant Weight Loss After Dopamine Agonist Treatment
por: Ali, Muzaffar, et al.
Publicado: (2021)

Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report
por: Koguchi, Motofumi, et al.
Publicado: (2019)

SAT-247 Use of Double Dopamine Agonists in Giant Prolactinomas: A Series of 6 Cases
por: Kuan, Yueh Chien
Publicado: (2020)

MON-293 The Prevalence of Impulse Control Disorders in Patients with Acromegaly and Prolactinomas Treated with Dopamine Agonists
por: Ozkaya, Hande Mefkure, et al.
Publicado: (2020)

FRI303 PRL-R Variants Are Not Only Associated With Prolactinomas But Also With Dopamine Agonist Resistance
por: de Castro Moreira, Andrea Ramos, et al.
Publicado: (2023)

Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report
por: Takeno, Ayumu, et al.
Publicado: (2019)

Low Serum Level of the Endogenous Secretory Receptor for Advanced Glycation End Products (esRAGE) Is a Risk Factor for Prevalent Vertebral Fractures Independent of Bone Mineral Density in Patients With Type 2 Diabetes
por: Yamamoto, Masahiro, et al.
Publicado: (2009)

Delayed presentation of late-onset cerebrospinal fluid rhinorrhoea following dopamine agonist therapy for giant prolactinoma
por: Prague, J K, et al.
Publicado: (2014)

Pituitary Prolactinoma with Amyloid Deposits: Surgery or Dopamine Agonists? Review of Previous Reports and New Recommendations for Management
por: Prabhu, Santosh, et al.
Publicado: (2019)

The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study
por: Ke, Xiaoan, et al.
Publicado: (2022)

The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas
por: Wang, Shuman, et al.
Publicado: (2021)

Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis
por: Cai, Xiangming, et al.
Publicado: (2022)

FRI305 Impulse Control Disorders In Patients With Prolactinomas And Non-Functioning Pituitary Adenomas Treated With Dopamine Agonists
por: Kolitz, Tamara, et al.
Publicado: (2023)

Phloretin Promotes Adipogenesis via Mitogen-Activated Protein Kinase Pathways in Mouse Marrow Stromal ST2 Cells
por: Takeno, Ayumu, et al.
Publicado: (2018)

Phloretin Suppresses Bone Morphogenetic Protein-2-Induced Osteoblastogenesis and Mineralization via Inhibition of Phosphatidylinositol 3-kinases/Akt Pathway
por: Takeno, Ayumu, et al.
Publicado: (2019)

Is prolactin receptor signaling a target in dopamine-resistant prolactinomas?
por: Ferraris, Jimena
Publicado: (2023)

SAT-455 Analysis of a Group of Prolactinomas Resistant to Treatment with Dopamine Agonists at a University Hospital in Buenos Aires, Argentina
por: Gonzalez Pernas, Mariana, et al.
Publicado: (2019)

PMON78 Improvement in Resistant Hypogonadism with use of Clomiphene in Prolactinomas Treated with Dopamine Agonist: A Case Study and Review of Literature
por: Singh, Julie, et al.
Publicado: (2022)

Adiponectin and AMP kinase activator stimulate proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells
por: Kanazawa, Ippei, et al.
Publicado: (2007)

Advanced Glycation End Products, Diabetes, and Bone Strength
por: Yamamoto, Masahiro, et al.
Publicado: (2016)

Successful treatment of a prolactinoma with the antipsychotic drug aripiprazole
por: Bakker, Ilse C A, et al.
Publicado: (2016)

SAT-478 Successful Management of an Atypical Prolactinoma with Radiotherapy
por: Bowes, Christa, et al.
Publicado: (2019)

Expression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas
por: Gao, Zhichao, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ncm1qfnnq5ef32djviisg2e95d